Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells.

Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells.

Treatment for the lethal primary adult brain tumor glioblastoma (GBM) includes the chemotherapy temozolomide (TMZ), but TMZ resistance is common and correlates with promoter methylation of the DNA repair enzyme O-6-methylguanine-DNA methyltransferase (MGMT). To improve treatment of GBMs, including t...

Full description

Bibliographic Details
Main Authors: Sarah E Williford, Catherine J Libby, Adetokunbo Ayokanmbi, Arphaxad Otamias, Juan J Gordillo, Emily R Gordon, Sara J Cooper, Matthew Redmann, Yanjie Li, Corinne Griguer, Jianhua Zhang, Marek Napierala, Subramaniam Ananthan, Anita B Hjelmeland
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0250649

Internet

https://doi.org/10.1371/journal.pone.0250649

Similar Items